237 related articles for article (PubMed ID: 17962941)
21. Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer.
Betts G; Jones E; Junaid S; El-Shanawany T; Scurr M; Mizen P; Kumar M; Jones S; Rees B; Williams G; Gallimore A; Godkin A
Gut; 2012 Aug; 61(8):1163-71. PubMed ID: 22207629
[TBL] [Abstract][Full Text] [Related]
22. High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients.
Frey DM; Droeser RA; Viehl CT; Zlobec I; Lugli A; Zingg U; Oertli D; Kettelhack C; Terracciano L; Tornillo L
Int J Cancer; 2010 Jun; 126(11):2635-43. PubMed ID: 19856313
[TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer.
Cianchi F; Cortesini C; Fantappiè O; Messerini L; Sardi I; Lasagna N; Perna F; Fabbroni V; Di Felice A; Perigli G; Mazzanti R; Masini E
Clin Cancer Res; 2004 Apr; 10(8):2694-704. PubMed ID: 15102673
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
25. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
26. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis.
Cui G; Yuan A; Li Z; Goll R; Florholmen J
Sci Rep; 2020 Apr; 10(1):5892. PubMed ID: 32246094
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of naive CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation.
Mahic M; Yaqub S; Bryn T; Henjum K; Eide DM; Torgersen KM; Aandahl EM; Taskén K
J Leukoc Biol; 2008 May; 83(5):1111-7. PubMed ID: 18270250
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer.
Bauer K; Michel S; Reuschenbach M; Nelius N; von Knebel Doeberitz M; Kloor M
Fam Cancer; 2011 Sep; 10(3):557-65. PubMed ID: 21598004
[TBL] [Abstract][Full Text] [Related]
29. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells.
Yaqub S; Taskén K
Crit Rev Oncog; 2008; 14(1):57-77. PubMed ID: 19105570
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of FoxP3+ T regulatory cells in the tumor microenvironment of human colorectal adenomas.
Hua W; Yuan A; Zheng W; Li C; Cui J; Pang Z; Zhang L; Li Z; Goll R; Cui G
Pathol Res Pract; 2016 Feb; 212(2):106-12. PubMed ID: 26724144
[TBL] [Abstract][Full Text] [Related]
31. DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.
Hu J; Wang Z; Chen Z; Li A; Sun J; Zheng M; Wu J; Shen T; Qiao J; Li L; Li B; Wu D; Xiao Q
Biomed Pharmacother; 2020 Jul; 127():110229. PubMed ID: 32559853
[TBL] [Abstract][Full Text] [Related]
32. T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer.
Kemp RA; Black MA; McCall J; Yoon HS; Phillips V; Anjomshoaa A; Reeve AE
J Exp Clin Cancer Res; 2011 Aug; 30(1):78. PubMed ID: 21864372
[TBL] [Abstract][Full Text] [Related]
33. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity.
Nakanishi M; Menoret A; Tanaka T; Miyamoto S; Montrose DC; Vella AT; Rosenberg DW
Cancer Prev Res (Phila); 2011 Aug; 4(8):1198-208. PubMed ID: 21576350
[TBL] [Abstract][Full Text] [Related]
34. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
Tanaka S; Tatsuguchi A; Futagami S; Gudis K; Wada K; Seo T; Mitsui K; Yonezawa M; Nagata K; Fujimori S; Tsukui T; Kishida T; Sakamoto C
Gut; 2006 Jan; 55(1):54-61. PubMed ID: 16085694
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
36. The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells.
Chien CC; Ko CH; Shen SC; Yang LY; Chen YC
J Cell Physiol; 2012 Aug; 227(8):3128-37. PubMed ID: 22170686
[TBL] [Abstract][Full Text] [Related]
37. Foxp3 expression in CD4
Zhu XW; Zhu HZ; Zhu YQ; Feng MH; Qi J; Chen ZF
J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):677-682. PubMed ID: 27752897
[TBL] [Abstract][Full Text] [Related]
38. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer.
Lin YC; Mahalingam J; Chiang JM; Su PJ; Chu YY; Lai HY; Fang JH; Huang CT; Chiu CT; Lin CY
Int J Cancer; 2013 Mar; 132(6):1341-50. PubMed ID: 22907255
[TBL] [Abstract][Full Text] [Related]
39. Interplay between post-translational cyclooxygenase-2 modifications and the metabolic and proteomic profile in a colorectal cancer cohort.
Prieto P; Jaén RI; Calle D; Gómez-Serrano M; Núñez E; Fernández-Velasco M; Martín-Sanz P; Alonso S; Vázquez J; Cerdán S; Peinado MÁ; Boscá L
World J Gastroenterol; 2019 Jan; 25(4):433-446. PubMed ID: 30700940
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.
Zhen YH; Liu XH; Yang Y; Li B; Tang JL; Zeng QX; Hu J; Zeng XN; Zhang L; Wang ZJ; Li XY; Ge HX; Winqvist O; Hu PS; Xiu J
Cancer Immunol Immunother; 2015 Sep; 64(9):1083-93. PubMed ID: 25990075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
